Oral administration of Rosuvastatin, a widely used lipid-lowering drug to STZ-induced diabetic rats, alleviated cardiac dysfunction, and the suppression of inflammasome activation of NLRP3 has been found to strengthen cardiac function, reduce interstitial fibrosis and mitigate cardiac structural disorders in individuals with DCM [97]. Here, NLRP3 is linked to familial dilated cardiomyopathy.